Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

1 results
4:10 PM, Oct 06, 2017  |  BioCentury | Finance

Coasting on catalysts

is Phase II data from Regeneron Pharmaceuticals Inc. 's trials of nesvacumab, a mAb against angiopoietin 2
ANG2 ; ANGPT2), in combination with Eylea aflibercept to treat wet age-related macular degeneration (AMD …